Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.
A legfontosabb adatok
- Ki végzi
- CHU de Quebec-Universite Laval
- Hol
- Kanada11 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Felfüggesztve
- Résztvevők
- 500 fő, tervezett
- Kezdés
- 2022. szept. 1.
- Várható befejezés
- 2035. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)
- Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):
- Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)
- Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)
- Report and compare the biochemical disease free survival (bDFS)
- Report and compare the disease free survival (DFS)
- Report and compare the metastase free survival (MFS)
- Report and compare the overall survival (OS)
- A regiszteradat frissítve
- 2025. szeptember 12.
- Miért állt le
- amendment to be done, adding 200 patients
Ki vehet részt
- Életkor
- 18 év – 95 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Histopathologically confirmed adenocarcinoma of the prostate
- All clinical stages with lymph node involvement risk needing pelvis RT
- Stage Mx or M0
- Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines
- Having the ability to give free and informed consent
Ki nem vehet részt
- IPSS Score > 20 with alpha-blocking medication
- Prior pelvic radiotherapy,
- History of active collagenosis (Lupus, Scleroderma, Dermatomyositis)
- Past history of Inflammatory Bowell Disease
- Clinical stage M1
- Bilateral hip prosthesis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Randomized Phase III study, comparing pelvic ultra-hypo fractionated radiotherapy (UHF: 5Gy/fraction) to a standard or moderate hypo-fractionation (1.8-2.15Gy/fraction), both associated to an HDR prostate +/- adjacent seminal vesicles brachytherapy boost (HDR-BT)+ ADT according to NCCN guidelines. Considering that the calculated bio-equivalent doses to the tumor are similar for all treatment options, the UHF technique is deemed to be non-inferior to the standard approach. Treatment acceptability, tolerance and adverse events will be reported and compared for non-inferiority as the primary objective. Secondary objectives are biochemical control, metastasis-free, disease specific and overall survival.
A vizsgálat 2 csoportja
- ultra hypo fractionation radiation therapy (UHF)A vizsgált kezelés
5 radiation treatments (5 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given every other day over 2 weeks for a total of 25 Gy.
Kezelés: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS), Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):, Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM), Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE), Report and compare the biochemical disease free survival (bDFS), Report and compare the disease free survival (DFS), Report and compare the metastase free survival (MFS) és Report and compare the overall survival (OS)
- standard of care fractionation (SOC)Már használt kezelés, összehasonlításként
20-25 radiation treatments (range: 1,8 to 2,15 Gy per fraction) to the prostate, seminal vesicle and pelvic nodes given in 20-25 working day treatments over 4-5 weeks for a total of 43 Gy to 46 Gy.
Kezelés: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS), Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):, Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM), Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE), Report and compare the biochemical disease free survival (bDFS), Report and compare the disease free survival (DFS), Report and compare the metastase free survival (MFS) és Report and compare the overall survival (OS)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial. (PCS-XI)
- A regiszteradat frissítve
- 2025. szeptember 12.